Combination of olverembatinib (HQP1351) with BCL-2 inhibitor lisaftoclax (APG-2575) overcomes resistance in gastrointestinal stromal tumors (GISTs)

Min, P; Wang, GF; Liang, E; Wu, BX; Yu, HD; Yang, DJ; Zhai, YF

CANCER RESEARCH, 2023; 83 (7):